Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab

Abstract

The fully human monoclonal antibody nivolumab binds to the programmed death-1 (PD-1) receptor, blocking interactions between PD-1 and its ligands on tumor cells and preventing T cell exhaustion in patients with cancer. The potential for corrected QT interval (QTc) prolongation was assessed in a subset of patients enrolled in a phase 2 dose-ranging study of… (More)
DOI: 10.1007/s00280-016-2980-3

6 Figures and Tables

Topics

  • Presentations referencing similar topics